PDF(Pubmed)
Abstract：
UNASSIGNED: Patients with high-grade gliomas are at risk of developing increased intracranial hypertension (ICHT) in relation to the increase in volume of their tumor. ICP change cannot be measured by invasive method but can be estimated by using routine clinical signs, in combination with a standard imaging method, magnetic resonance imaging (MRI). A non-invasive monitoring of ICP could be of interest in high-grade glioma, in particular after radiotherapy treatment with as major side effect a cerebral oedema.
UNASSIGNED: This prospective clinical study aimed to compare the ICP changes (estimated by a non-invasive method based upon distortion product otoacoustic emissions (DPOAE) monitoring) with volume changes observed on MRI in patients with high-grade gliomas treated with radiotherapy. DPOAE measurements were performed one month after the end of radiotherapy and then every 3 months for one year. At each visit, the patient also underwent MRI as well as an evaluation of clinical signs.
UNASSIGNED: The variation in the estimate of intracranial pressure readout measured at each follow-up visit (in absolute value with respect to the baseline measurements) was significantly associated with the variation of T2/FLAIR volume (n=125; p<0.001) with a cut off value of change ICP readout of 40.2 degrees (e.i. an estimated change of 16 mm Hg).
UNASSIGNED: The GMaPIC trial confirm the hypothesis that the ICP change estimated by DPOAEs measurement using a non-invasive medical device is correlated with the change of the tumor or edema in high grade glioma after radiotherapy. The device could thus become an easy-to-use and non-invasive intracranial pressure monitoring tool for these patients.
UNASSIGNED: Clinicaltrials.gov, identifier (NCT02520492).
UNASSIGNED: This prospective clinical study aimed to compare the ICP changes (estimated by a non-invasive method based upon distortion product otoacoustic emissions (DPOAE) monitoring) with volume changes observed on MRI in patients with high-grade gliomas treated with radiotherapy. DPOAE measurements were performed one month after the end of radiotherapy and then every 3 months for one year. At each visit, the patient also underwent MRI as well as an evaluation of clinical signs.
UNASSIGNED: The variation in the estimate of intracranial pressure readout measured at each follow-up visit (in absolute value with respect to the baseline measurements) was significantly associated with the variation of T2/FLAIR volume (n=125; p<0.001) with a cut off value of change ICP readout of 40.2 degrees (e.i. an estimated change of 16 mm Hg).
UNASSIGNED: The GMaPIC trial confirm the hypothesis that the ICP change estimated by DPOAEs measurement using a non-invasive medical device is correlated with the change of the tumor or edema in high grade glioma after radiotherapy. The device could thus become an easy-to-use and non-invasive intracranial pressure monitoring tool for these patients.
UNASSIGNED: Clinicaltrials.gov, identifier (NCT02520492).
摘要：
■与肿瘤体积的增加有关，患有高级别神经胶质瘤的患者有发生颅内高压（ICHT）增加的风险。ICP变化不能通过侵入性方法测量，但可以通过使用常规临床体征来估计。结合标准成像方法，磁共振成像（MRI）。ICP的非侵入性监测可能对高级别神经胶质瘤感兴趣，特别是在放射治疗后，主要副作用是脑水肿。
■这项前瞻性临床研究旨在比较ICP变化（通过基于畸变产物耳声发射（DPOAE）监测的非侵入性方法估算）与MRI上观察到的体积变化接受放射治疗的高级别神经胶质瘤。放疗结束后一个月进行DPOAE测量，然后每3个月进行一次，为期一年。每次访问,患者还接受了MRI检查以及临床体征评估.
■每次随访时测量的颅内压读数估计值的变化（相对于基线测量的绝对值）与T2/FLAIR体积的变化显着相关（n=125；p<0.001），ICP读数的变化截止值为40.2度（例如，估计的变化为16mmHg）。
■GMaPIC试验证实了以下假设：使用非侵入性医疗设备通过DPOAEs测量估计的ICP变化与放疗后高级别神经胶质瘤的肿瘤或水肿变化相关。因此，该设备可以成为这些患者的易于使用且无创的颅内压监测工具。
■Clinicaltrials.gov，标识符(NCT02520492)。
■这项前瞻性临床研究旨在比较ICP变化（通过基于畸变产物耳声发射（DPOAE）监测的非侵入性方法估算）与MRI上观察到的体积变化接受放射治疗的高级别神经胶质瘤。放疗结束后一个月进行DPOAE测量，然后每3个月进行一次，为期一年。每次访问,患者还接受了MRI检查以及临床体征评估.
■每次随访时测量的颅内压读数估计值的变化（相对于基线测量的绝对值）与T2/FLAIR体积的变化显着相关（n=125；p<0.001），ICP读数的变化截止值为40.2度（例如，估计的变化为16mmHg）。
■GMaPIC试验证实了以下假设：使用非侵入性医疗设备通过DPOAEs测量估计的ICP变化与放疗后高级别神经胶质瘤的肿瘤或水肿变化相关。因此，该设备可以成为这些患者的易于使用且无创的颅内压监测工具。
■Clinicaltrials.gov，标识符(NCT02520492)。
